“This project will allow us to significantly reduce the complexity and cost of CO2 capture and biofixation from all sources, whether it is from utility companies, cement manufacturing, or chemical plants."
“This is a great opportunity to carry our efforts beyond Kentucky and the United States,” said Seth DeBolt, director of the James B. Beam Institute for Kentucky Spirits. “To partner with such an established institute will elevate the efforts we’ve already begun at the Beam Institute.”
The funding will further ongoing substance use disorder treatment research in collaboration with Sharon Walsh at the UK Center on Drug and Alcohol Research (CDAR) and Mei-Chuan Ko at the Wake Forest School of Medicine.
PDS0203 stands out among COVID-19 vaccines currently in development because it includes a vaccine technology pioneered by PDS Biotech called Versamune®, which stimulates important parts of the immune system to activate T cells.
“We all want to grow Kentucky’s tech sector and create the high-paying, knowledge-based jobs that follow. A big part of doing so is turning Kentucky’s own academic research and development capabilities into commercially viable products and startups.”
Supported by XLerateHealth, a health care startup accelerator in Louisville, Kentucky, and by UK, EnRICH is an outgrowth of NIH funding UK received in October 2018 — $3.5 million over three years — to create the XLerator Network.
The new potential treatment has been added to the University of Kentucky’s innovative clinical trial for experimental COVID-19 therapies, which was launched by leaders from UK’s Markey Cancer Center, College of Medicine and College of Pharmacy in May.
UK announced a research collaboration with Atomwise, an industry leader in using artificial intelligence (AI) for small molecule discovery, to explore potential COVID-19 therapies.
UK and ArtemiLife Inc. will collaborate on a clinical study using the extract of a medicinal plant grown in Kentucky to test for anti-cancer activity of Artemisia annua and to determine the recommended dose of Artemisia annua for future clinical trials.
UK's Office of Technology Commercialization announces its first-ever license agreement with Lexmark International Inc. involving a project led by Joshua Werner exploring the recovery and recycling of precious metals.
